Literature DB >> 17034574

Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru.

I Best1, V Adaui, K Verdonck, E González, M Tipismana, D Clark, E Gotuzzo, G Vanham.   

Abstract

Human T-lymphotropic virus type 1 (HTLV-1) is the aetiological agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The objective of this study is to identify which ex vivo and in vivo markers are associated independently with HAM/TSP in a Peruvian population. Eighty-one subjects (33 men/48 women) were enrolled: 35 presented with HAM/TSP, 33 were asymptomatic HTLV-1 carriers (ACs) and 13 were HTLV-1-seronegative controls (SCs). Ex vivo markers included T cell proliferation and Th1 [interferon (IFN)-gamma], Th2 [interleukin (IL)-4, IL-5], proinflammatory [tumour necrosis factor (TNF)-alpha] and anti-inflammatory (IL-10) cytokine production in non-stimulated peripheral blood mononuclear cell (PBMC) cultures. In vivo CD4(+) T cell count, markers of Th1 [interferon-inducible protein (IP)-10] and Th2 (sCD30) activity in plasma and HTLV-1 proviral load in PBMCs were also evaluated. In univariate analysis, several markers, including T cell proliferation, IFN-gamma, IP-10, sCD30 and proviral load were associated with HAM/TSP, but in a multiple logistic regression analysis only the proviral load remained associated significantly with disease manifestation [adjusted OR 9.10 (1.24-66.91)]. Our findings suggest that HAM/TSP is associated primarily with proviral load, whereas the observed association with some immune markers seems secondary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17034574      PMCID: PMC1942059          DOI: 10.1111/j.1365-2249.2006.03208.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

1.  Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection.

Authors:  A Manns; W J Miley; R J Wilks; O S Morgan; B Hanchard; G Wharfe; B Cranston; E Maloney; S L Welles; W A Blattner; D Waters
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

Review 2.  The biology of chemokines and their receptors.

Authors:  D Rossi; A Zlotnik
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Prospective study of HTLV-I infection in an initially asymptomatic cohort.

Authors:  G P Taylor; J H Tosswill; E Matutes; S Daenke; S Hall; B J Bain; R Davis; D Thomas; M Rossor; C R Bangham; J N Weber
Journal:  J Acquir Immune Defic Syndr       Date:  1999-09-01       Impact factor: 3.731

4.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

Review 5.  The immune response to HTLV-I.

Authors:  C R Bangham
Journal:  Curr Opin Immunol       Date:  2000-08       Impact factor: 7.486

6.  A quantification of human cells using an ERV-3 real time PCR assay.

Authors:  C C Yuan; W Miley; D Waters
Journal:  J Virol Methods       Date:  2001-02       Impact factor: 2.014

Review 7.  Human T-cell lymphotropic virus-I in Latin America.

Authors:  E Gotuzzo; C Arango; A de Queiroz-Campos; R E Istúriz
Journal:  Infect Dis Clin North Am       Date:  2000-03       Impact factor: 5.982

8.  Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors.

Authors:  E M Carvalho; O Bacellar; A F Porto; S Braga; B Galvão-Castro; F Neva
Journal:  J Acquir Immune Defic Syndr       Date:  2001-05-01       Impact factor: 3.731

9.  HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy.

Authors:  K J Jeffery; K Usuku; S E Hall; W Matsumoto; G P Taylor; J Procter; M Bunce; G S Ogg; K I Welsh; J N Weber; A L Lloyd; M A Nowak; M Nagai; D Kodama; S Izumo; M Osame; C R Bangham
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

10.  The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection.

Authors:  K J Jeffery; A A Siddiqui; M Bunce; A L Lloyd; A M Vine; A D Witkover; S Izumo; K Usuku; K I Welsh; M Osame; C R Bangham
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

View more
  12 in total

1.  Study of autoantibodies in patients with keratoconjunctivitis sicca infected by the human T cell lymphotropic virus type 1.

Authors:  Ana Karina Ferraz-Chaoui; Ajax Mercês Atta; Maria Luiza Sousa Atta; Bernardo Galvão-Castro; Mittermayer B Santiago
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

2.  Pentosan polysulfate treatment ameliorates motor function with increased serum soluble vascular cell adhesion molecule-1 in HTLV-1-associated neurologic disease.

Authors:  Tatsufumi Nakamura; Katsuya Satoh; Taku Fukuda; Ikuo Kinoshita; Yoshihiro Nishiura; Kunihiko Nagasato; Atsushi Yamauchi; Yasufumi Kataoka; Tadahiro Nakamura; Hitoshi Sasaki; Kenji Kumagai; Masami Niwa; Mitsuru Noguchi; Hideki Nakamura; Noriyuki Nishida; Atsushi Kawakami
Journal:  J Neurovirol       Date:  2014-03-27       Impact factor: 2.643

3.  Utility of HTLV proviral load quantification in diagnosis of HTLV-1-associated myelopathy requires international standardization.

Authors:  Maria Fernanda Rios Grassi; Viviana Nilla Olavarria; Ramon de Almeida Kruschewsky; Yoshihisa Yamano; Steven Jacobson; Graham P Taylor; Fabiola Martin; Bernardo Galvão-Castro
Journal:  J Clin Virol       Date:  2013-09-13       Impact factor: 3.168

4.  IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population.

Authors:  Ivan Best; Giovanni López; Kristien Verdonck; Elsa González; Martín Tipismana; Eduardo Gotuzzo; Guido Vanham; Daniel Clark
Journal:  Immunology       Date:  2009-02-17       Impact factor: 7.397

5.  Human T Lymphotropic Virus Type I (HTLV-I) is a Risk Factor for Coronary Artery Disease.

Authors:  Reza Farid Hosseni; Farahzad Jabbari; Mahmoud Shabestari; S A Rahim Rezaee; Yousef Gharivani; Narges Valizadeh; Mansoreh Sobhani; Toktam Moghiman; Farnaz Mozayani
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

6.  Evaluation of HTLV-1 activity in HAM/TSP patients using proviral load and Tax mRNA expression after In Vitro lymphocyte activation.

Authors:  Atefeh Yari; Seyyed Abdolrahim Rezaee; Narges Valizadeh; Taraneh Rajaee; Seyyed Mohammad Jazayeri; Mojdeh Soltani; Mehdi Norouzi
Journal:  Iran J Basic Med Sci       Date:  2014-07       Impact factor: 2.699

7.  Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy.

Authors:  Britta Moens; Daniele Decanine; Soraya Maria Menezes; Ricardo Khouri; Gilvanéia Silva-Santos; Giovanni Lopez; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Ramon de Almeida Kruschewsky; Bernardo Galvão-Castro; Anne-Mieke Vandamme; Johan Van Weyenbergh
Journal:  PLoS Negl Trop Dis       Date:  2012-07-24

8.  Leukotrienes are upregulated and associated with human T-lymphotropic virus type 1 (HTLV-1)-associated neuroinflammatory disease.

Authors:  Bruno Caetano Trindade; Carlos Artério Sorgi; Larissa Deadame de Figueiredo Nicolete; Tathiane Maistro Malta; Mariana Tomazini Pinto; Osvaldo Massaiti Takayanagui; Dimas Tadeu Covas; Olindo Assis Martins Filho; Simone Kashima; Lúcia Helena Faccioli
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  High frequency of CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response.

Authors:  Frederic Toulza; Adrian Heaps; Yuetsu Tanaka; Graham P Taylor; Charles R M Bangham
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

10.  Outcome of Intravenous Immunoglobulin-Transmitted HTLV-I, Hepatitis B, Hepatitis C, and HIV infections.

Authors:  Mohsen Foroughipour; Farahzad Jabbari Azad; Reza Farid Hosseini; Abbas Shirdel; Amir Reza Khalighi; Hadis Yousefzadeh; Homa Sadri; Toktam Moghiman; Hossein Hekmatkhah
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.